Chemours Co (CC) Form 8-K — Nov 2, 2026
Chemours reported Q3 2026 net sales of $1.54 billion, up 3% year over year, with net income of $196 million ($1.29 diluted EPS) versus $46 million ($0.31) a year ago. GAAP results were boosted by $150 million in PFAS insurance proceeds tied to the New Jersey consent order; adjusted net income was $31 million ($0.21 EPS) versus $26 million ($0.17) previously. Performance was mixed by segment: Titanium Technologies sales rose 11% with adjusted EBITDA up 240% to $85 million on pricing execution, APM Performance Solutions grew 26% on data center and semiconductor demand, while TSS sales fell 9% and its adjusted EBITDA dropped 30% on softer stationary AC aftermarket volumes.
Key figures
- Eps
- 1.29
- Revenue
- 1540000000
- Guidance
- Q4 2026 net sales down 5-10% sequentially, Adjusted EBITDA $160-185M; FY2026 net sales up ~2%, Adjusted EBITDA $775-800M, capex $220-230M, free cash flow conversion above 15%, net leverage below 4.2x.
- Net Income
- 196000000
- Total Debt
- 3900000000
- Revenue Yoy
- 3%
- Total Assets
- 7293000000
- Cash Position
- 698000000
- Shares Outstanding
- 150519801
- Adjusted eps
- $0.21 vs $0.17 prior year
- Tt net sales
- $680M, up 11% YoY; TT adjusted EBITDA $85M vs $25M
- Apm net sales
- $337M, up 8% YoY; APM adjusted EBITDA $24M, up 71%
- Tss net sales
- $510M, down 9% YoY; TSS adjusted EBITDA $136M, down 30%
- Free cash flow
- $98M
- Adjusted ebitda
- $200M vs $189M prior year
- Total liquidity
- $1.7B
- Net leverage ratio
- 4.3x
- Adjusted net income
- $31M
- Operating cash flow
- $149M
- Kuan yin sale proceeds
- ~$340M net consideration
- Pfas insurance proceeds
- $150M
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.